Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.
about
Rituximab for rheumatoid arthritisOfatumumab for rheumatoid arthritisRituximab for rheumatoid arthritisOfatumumabB cells as a therapeutic target in autoimmune diseaseCharacterization of lymphocyte populations in nonspecific interstitial pneumoniaUse of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.B cell depletion in autoimmune disease.Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.The potential utility of B cell-directed biologic therapy in autoimmune diseases.Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with RituximabB cells limit repair after ischemic acute kidney injury.B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis.Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.Novel applications of Rituximab in dermatological disordersNon-infectious pulmonary toxicity of rituximab: a systematic review.Cytokine-mediated bone destruction in rheumatoid arthritis.Recent progress in the understanding of B-cell functions in autoimmunity.Chronic graft-versus-host disease: clinical manifestation and therapy.Rituximab: clinical development and future directions.From T to B and back again: positive feedback in systemic autoimmune disease.Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.Treating human autoimmune disease by depleting B cellsEnumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis.CD20-mediated apoptosis: signalling through lipid rafts.Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritisThe plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritisRheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases.B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experienceRituximab (Rituxan/MabThera): the first decade (1993-2003).B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.
P2860
Q24186568-884C8546-275A-46B4-86CD-27F5498324EDQ24202719-5B2F2928-47F8-4CE4-990C-802801059715Q24242554-2FAA5E90-5BCF-4890-858F-6BF3960BA2CEQ24651912-F93483B0-A73E-48BB-A69C-AEB03F848848Q24804504-584D2202-FFF4-46E4-9A74-F780CAEC56F8Q24815753-29E57403-57CE-4F96-A4D7-E99B6D751FF8Q30807010-84CF5AC8-7D8A-4067-8A29-4441CCD60570Q33361142-7CCB6272-1BBA-4B77-8F75-279F7A58DD15Q33370836-A6C8EC9E-6C39-4E38-80C2-AEB6DEF1FB07Q33377109-649D0BFC-1585-4213-A795-5ECC2282EE1DQ33421964-15CFC98A-5F39-4FF2-B1EA-9C75AF658F6AQ33741009-1208C5FA-0B91-4F4B-93F5-4A91B72F7C5FQ33748553-87F7F0E7-329E-4CFF-8873-067F6CA55EA7Q33806313-1FEF74D8-10BE-4758-AD68-78582B6135ECQ34085036-3F3A2DBC-D3CD-428C-B278-02AD243292B4Q34087599-E6D07909-DF02-4412-9413-64D43776DC27Q34096300-B2432CDC-BEA7-4B6A-8361-210B98619BD1Q34252489-B16FACF7-B9CB-4B33-A9CC-1D8F54C196BDQ34299834-397D1B1A-D743-4335-8EF7-926451DF4AB0Q34339695-764EC969-C903-43D8-91B7-DEAA630C6BD6Q34482081-E38CF749-ECC4-4496-B0FE-91228CE3C888Q34572168-F695F23B-0A68-414E-824C-05FA45717035Q34656882-37C01E5F-6841-437C-8E4B-D13BCE173515Q34672043-274E80E2-9D13-4211-AB5E-C62D342A9E84Q34831296-21305EA8-F8A9-498C-8A46-9459B0DD311CQ34848963-373065EA-DDBC-4575-B2E2-CCF0FE18A14DQ34896320-173C36FC-5FC2-4E20-A8FE-3E15623FC4CDQ34969960-E905FBAE-837A-4B60-9264-FD46CAD07760Q35070822-404846F5-736A-4927-8B37-2295DCF80291Q35083758-3FE7EA79-5484-492C-B57B-3235C395A69FQ35085103-30789332-6258-4CFC-9F91-8191E4ABEBE1Q35102984-66A7D9CD-99BF-4B52-AE16-066CD9D69CECQ35181271-07D2CF2E-B895-42B7-8259-BF19C3EFDF7AQ35551028-70326B3F-69C2-4E2A-87C8-3DF0E76D72BCQ35552189-19658001-0410-4B95-A37C-4DD082546824Q35553501-50627726-5C57-43B7-A66C-D3E3070AA819Q35611848-839B8703-7C98-4849-B6BD-FCF925C931DEQ35627016-24F01BB9-DDB1-40DF-945D-442C9E68F7DAQ35638252-B0DA5790-0606-42BF-877B-2C62F9719F59Q35654669-C3041943-D0DF-4F2C-812E-F31E5277A9DF
P2860
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@ast
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@en
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@nl
type
label
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@ast
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@en
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@nl
prefLabel
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@ast
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@en
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@nl
P2860
P356
P1433
P1476
Sustained improvement in rheum ...... gned to deplete B lymphocytes.
@en
P2093
Cambridge G
Edwards JC
P2860
P304
P356
10.1093/RHEUMATOLOGY/40.2.205
P577
2001-02-01T00:00:00Z